AVIR Atea Pharmaceuticals, Inc.
$5.31▲ +2.51%
Healthcare
Other
After hours
$5.35▲ +0.75%
Sep 11, 6:44 PM ET
Volume 489.5K
Avg Volume (10D) 228.5K
Key Metrics & Fundamentals
Market Cap
$425.89M
P/E Ratio
–
Div Yield
–%
52W Range
2.78 - 6.45
% vs 50 MA
4.51%
% vs 200 MA
14.05%
RSI-14
49.7
MACD Histogram
-0.0500
Beta (1Y vs SPY)
0.67
Free Cash Flow
-$37.08M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$35.00M
COGS
–
Operating Exp
$35.10M
Operating Income
-$35.10M
EBIT
-$35.10M
Pretax Income
-$32.91M
Net Income
-$32.93M
EPS (Diluted)
-0.41
Price & Volume History
Loading chart…
Recent News
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
GlobeNewswire · Sep 8, 2026 11:00 AM
Atea (AVIR) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 19, 2026 9:13 PM
Atea Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 13, 2026 12:55 AM
Atea Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · Aug 12, 2026 10:04 PM
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 12, 2026 8:05 PM
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
GlobeNewswire · Aug 5, 2026 11:00 AM
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data
BioPharma Dive · Jul 29, 2026 11:00 AM
Atea Pharmaceuticals Says Hepatitis C Drug Matches Gilead's in Pivotal Trial
Benzinga · Jul 29, 2026 9:45 AM
Atea Pharmaceuticals Says Combination Drug Meets Endpoints in Phase 3 Hepatitis C Trial
MT Newswires · Jul 28, 2026 12:27 PM
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
GlobeNewswire · Jul 28, 2026 11:00 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See AVIR's money flow as a full page
Social Sentiment
No Reddit posts found for AVIR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.